Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Plonmarlimab

Phase 3Monoclonal antibody

TTJ Biopharma Co., Ltd.

Plonmarlimab is one of 44 small molecule programs targeting Arthritis. It is currently in Phase 3.

3

Indications

3

Total Trials

2

Active Trials

43

Competitors

Pipeline

Status by Indication[3][1]

Indication

ArthritisActive, not recruiting

Macrophage Activation SyndromeActive, not recruiting

Relapsed/refractoryRecruiting

ArthritisPhase 2

Active, not recruiting

Macrophage Activation SyndromePhase 3

Active, not recruiting

Relapsed/refractoryPhase 3

Recruiting

Competition

Competitive Landscape

159 competitors in Arthritis

#DrugCompanyPhaseTrials

Cosentyx

Simponi

Johnson & Johnson

Taltz

Aleve

Alnylam Pharmaceuticals

Stelara

Johnson & Johnson

Bimzelx

Ilaris

Kenalog

BBassett Healthcare

Remicade

OOrganon and Co

Kenalog

BBausch Health Americas, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Relapsed/refractory

NCT07208058

Phase 2Not yet recruiting

Arthritis

NCT07453004

Clinical

Trials by Indication[1]

Arthritis1 trial

A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis

Not yet recruiting·TTJ Biopharma Co., Ltd.·Phase 2·NCT07453004·170 enrolled

Macrophage Activation Syndrome1 trial

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))

Completed·TTJ Biopharma Co., Ltd.·Phase 2·NCT07034209·18 enrolled

Relapsed/Refractory1 trial

An Open-label, Single-arm, Multicenter, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])

Recruiting·TTJ Biopharma Co., Ltd.·Phase 3·NCT07208058·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Plonmarlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plonmarlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plonmarlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TJ Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: TTJ Biopharma Co., Ltd.

Related News